VistaGen Therapeutics Inc (VTGN)
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company engaging in the treatment for individuals living with anxiety, depression and other central nervous system disorders. Co.'s product candidates include: fasedienol (PH94B), which is used for treatment of social anxiety disorder; Itruvone (PH10), which is used for depression disorders; PH80, which is used for treatment of both vasomotor symptoms (hot flashes) due to menopause and migraine headaches; PH15, which is used for treatment to improve cognitive impairment caused by mental fatigue and other disorders; and AV-101, which is an oral prodrug that targets the N-methyl-D-aspartate receptor.
|
Free VTGN Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 78th percentile
(ranked higher than approx. 78% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|